» Articles » PMID: 3422166

The Lipoprotein-associated Coagulation Inhibitor That Inhibits the Factor VII-tissue Factor Complex Also Inhibits Factor Xa: Insight into Its Possible Mechanism of Action

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 1988 Feb 1
PMID 3422166
Citations 88
Authors
Affiliations
Soon will be listed here.
Abstract

Blood coagulation is initiated when plasma factor VII(a) binds to its essential cofactor tissue factor (TF) and proteolytically activates factors X and IX. Progressive inhibition of TF activity occurs upon its addition to plasma. This process is reversible and requires the presence of VII(a), catalytically active Xa, Ca2+, and another component that appears to be associated with the lipoproteins in plasma, a lipoprotein-associated coagulation inhibitor (LACI). A protein, LACI(HG2), possessing the same inhibitory properties as LACI, has recently been isolated from the conditioned media of cultured human liver cells (HepG2). Rabbit antisera raised against a synthetic peptide based on the N-terminal sequence of LACI(HG2) and purified IgG from a rabbit immunized with intact LACI(HG2) inhibit the LACI activity in human serum. In a reaction mixture containing VIIa, Xa, Ca2+, and purified LACI(HG2), the apparent half-life (t1/2) for TF activity was 20 seconds. The presence of heparin accelerated the initial rate of inhibition threefold. Antithrombin III alpha alone had no effect, but antithrombin III alpha with heparin abrogated the TF inhibition. LACI(HG2) also inhibited Xa with an apparent t1/2 of 50 seconds. Heparin enhanced the rate of Xa inhibition 2.5-fold, whereas phospholipids and Ca2+ slowed the reaction 2.5-fold. Xa inhibition was demonstrable with both chromogenic substrate (S-2222) and bioassays, but no complex between Xa and LACI(HG2) could be visualized by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Nondenaturing PAGE, however, showed that LACI(HG2) bound to Xa but not to X or Xa inactivated by diisopropyl fluorophosphate. Thus, LACI(HG2) appears to bind to Xa at or near its active site. Bovine factor Xa lacking its gamma-carboxyglutamic acid-containing domain, BXa(-GD), through treatment with alpha-chymotrypsin, was used to further investigate the Xa requirement for VIIa/TF inhibition by LACI(HG2). LACI(HG2) bound to BXa(-GD) and inhibited its catalytic activity against a small molecular substrate (Spectrozyme Xa), though at a rate approximately sevenfold slower than native BXa. Preincubation of LACI(HG2) with saturating concentrations of BXa(-GD) markedly retarded the subsequent inhibition of BXa. The VII(a)/TF complex was not inhibited by LACI(HG2) in the presence of BXa(-GD), and further, preincubation of LACI(HG2) with BXa(-GD) slowed the inhibition of VIIa/TF after the addition of native Xa. The results are consistent with the hypothesis that inhibition of VII(a)/TF involves the formation of a VIIa-TF-XA-LACI complex that requires the GD of XA.(ABSTRACT TRUNCATED AT 400 WORDS)

Citing Articles

Extracellular vesicle tissue factor and tissue factor pathway inhibitor are independent discriminators of sepsis-induced coagulopathy.

Tobiasch A, Lehner G, Feistritzer C, Peer A, Zassler B, Neumair V Res Pract Thromb Haemost. 2024; 8(7):102596.

PMID: 39624584 PMC: 11609531. DOI: 10.1016/j.rpth.2024.102596.


Proteomic profile of extracellular vesicles in maternal plasma of women with fetal death.

Gallo D, Fitzgerald W, Romero R, Gomez-Lopez N, Gudicha D, Than N J Matern Fetal Neonatal Med. 2023; 36(1):2177529.

PMID: 36813269 PMC: 10395052. DOI: 10.1080/14767058.2023.2177529.


Haemostasis and Inflammatory Parameters as Potential Diagnostic Biomarkers for VTE in Trauma-Immobilized Patients.

Ramli N, Iberahim S, Noor N, Zulkafli Z, Tengku Md Shihabuddin T, Din M Diagnostics (Basel). 2023; 13(1).

PMID: 36611442 PMC: 9818770. DOI: 10.3390/diagnostics13010150.


Intersection of regulatory pathways controlling hemostasis and hemochorial placentation.

Muto M, Chakraborty D, Varberg K, Moreno-Irusta A, Iqbal K, Scott R Proc Natl Acad Sci U S A. 2021; 118(50).

PMID: 34876522 PMC: 8685669. DOI: 10.1073/pnas.2111267118.


Recent Advances in the Treatment of Hemophilia: A Review.

Marchesini E, Morfini M, Valentino L Biologics. 2021; 15:221-235.

PMID: 34163136 PMC: 8214539. DOI: 10.2147/BTT.S252580.